Molecular structure of Riociguat, CAS Number: 625115-55-1
Riociguat (CAS 625115-55-1)
Alternate Names:
N-[4,6-Diamino-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-pyrimidinyl]-N-methylcarbamic Acid Methyl Ester
CAS Number:
625115-55-1
Molecular Weight:
422.42
Molecular Formula:
C20H19FN8O2
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Riociguat functions by activating soluble guanylate cyclase (sGC), an enzyme in the cyclic guanosine monophosphate (cGMP) pathway. This activation results in elevated levels of cGMP, a pivotal messenger molecule that modulates various physiological processes. The increase in cGMP concentration facilitates the relaxation and dilation of the pulmonary arteries. This vasodilatory effect is instrumental in research focused on understanding the molecular dynamics of blood flow regulation and the mechanisms underlying pulmonary vascular resistance. By providing insights into the modulation of arterial dilation, Riociguat contributes to the exploration of potential strategies for modulating vascular function in various experimental applications.
Riociguat (CAS 625115-55-1) References
- Discovery of the Soluble Guanylate Cyclase Stimulator Vericiguat (BAY 1021189) for the Treatment of Chronic Heart Failure. | Follmann, M., et al. 2017. J Med Chem. 60: 5146-5161. PMID: 28557445
- Soluble Guanylate Cyclase Stimulators and Activators. | Sandner, P., et al. 2021. Handb Exp Pharmacol. 264: 355-394. PMID: 30689085
- Riociguat for treatment of pulmonary hypertension in COPD: a translational study. | Pichl, A., et al. 2019. Eur Respir J. 53: PMID: 30956210
- Riociguat, sildenafil and inhaled nitric oxide reduces pulmonary vascular resistance and improves right ventricular function in a porcine model of acute pulmonary embolism. | Schultz, J., et al. 2020. Eur Heart J Acute Cardiovasc Care. 9: 293-301. PMID: 31025569
- Riociguat Improves Pulmonary Hemodynamics in Patients with Inoperable Chronic Thromboembolic Pulmonary Hypertension. | Tsai, CH., et al. 2020. Acta Cardiol Sin. 36: 64-71. PMID: 31903010
- Riociguat ameliorates kidney injury and fibrosis in an animal model. | Sravani, S., et al. 2020. Biochem Biophys Res Commun. 530: 706-712. PMID: 32768189
- The effect of Riociguat on cardiovascular function and efficiency in healthy, juvenile pigs. | Naesheim, T., et al. 2020. Physiol Rep. 8: e14562. PMID: 32918535
- Triple oral combination therapy with macitentan, riociguat, and selexipag for pulmonary arterial hypertension. | Momoi, M., et al. 2021. Ther Adv Respir Dis. 15: 1753466621995048. PMID: 33627044
- Efficacy and safety of riociguat in the treatment of chronic thromboembolic pulmonary arterial hypertension: A meta-analysis. | Ying, M., et al. 2021. Medicine (Baltimore). 100: e26211. PMID: 34087896
- Riociguat can ameliorate bronchopulmonary dysplasia in the SU5416 induced rat experimental model. | Katsuragi, S., et al. 2021. Exp Lung Res. 47: 382-389. PMID: 34528477
- Repurposing Riociguat to Target a Novel Paracrine Nitric Oxide-TRPC6 Pathway to Prevent Podocyte Injury. | 't Hart, D., et al. 2021. Int J Mol Sci. 22: PMID: 34830371
- Riociguat attenuates the changes in left ventricular proteome and microRNA profile after experimental aortic stenosis in mice. | Benkner, A., et al. 2022. Br J Pharmacol. 179: 4575-4592. PMID: 35751875
- Soluble guanylate cyclase stimulator riociguat improves spatial memory in mice via peripheral mechanisms. | Nelissen, E., et al. 2022. Neurosci Lett. 788: 136840. PMID: 35985509
- Riociguat inhibits ultra-large VWF string formation on pulmonary artery endothelial cells from chronic thromboembolic pulmonary hypertension patients. | Jujo Sanada, T., et al. 2022. Pulm Circ. 12: e12146. PMID: 36568694
- Riociguat real-world use in patients with chronic thromboembolic pulmonary hypertension: A retrospective, observational cohort study in France. | Lamia, B., et al. 2022. Respir Med Res. 83: 100987. PMID: 36634552
Inhibitor of:
C20orf152, C22orf13, cGKI alpha, group X sPLA2, Guanylate Cyclase (GUCA), and PRDM6.Activator of:
c-GMP, C20orf152, C22orf13, cGKI, cGKI α, cGKII, CNG-β3, CNG-1β, GCS-α-2, GCS-β-1, GCS-β-2, GUCD1, HMW-Guanylin, MaxiKα, NPR-A, NPR-B, NPR-C, sGC α2, sGC β1, and sGC β2.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Riociguat, 5 mg | sc-476845 | 5 mg | $300.00 |